TP53 and sarcoma: reported that TP53 mutation in sarcomas is associated with shorter disease-free survival (HR = 1.63; 95% CI, 1.04–2.54; Cox p = 0.032) and better treatment outcomes with anthracyclines (OR = 3.70; 95% CI, 1.20–11.97; p = 0.02) [42, 176, 177, 179, 180].